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jo u rn al h om ep age: ww w.els evier .c o m/lo c ate / j j c cMore than 7.4 million deaths attributable to coronary heart
disease occur worldwide each year, most involving acute myocardial
infarction (AMI). In such situations, coronary reperfusion therapy
with percutaneous coronary intervention (PCI) has been widely
performed to patients suffering from AMI. On the other hand, the
process of restoring coronary blood ﬂow causes ischemia-reperfu-
sion injury in the ischemic myocardium, which limits the beneﬁcial
effects of reperfusion and contributes to left ventricular remodeling
and higher mortality rate despite successful reperfusion therapy
[1]. Until now, many trials have sought to identify ways to decrease
reperfusion injury and to improve clinical outcomes to prevent
reperfusion injury in patients undergoing PCI [2].
In this issue of the Journal of Cardiology, the ﬁndings by Arakawa
et al. may stimulate renewed interest in the clinical setting [3]. The
main ﬁnding was that lower n-3 polyunsaturated fatty acid (n-3
PUFA) levels can predict incidence of reperfusion injury after
primary PCI to AMI patients. n-3 PUFAs have unique actions such as
inhibition of platelet aggregation, anti-atherosclerosis effects, and
ameliorating endothelial function [4–6]. Previous studies have
shown that treatment with n-3 PUFAs improves clinical outcomes
in patients with ischemic heart disease [7,8]. Some mechanisms for
effects of n-3 PUFAs in patients with ischemic heart disease are
possible to explain. A study in which coronary plaque components
were evaluated by intravascular ultrasound clearly showed that
lower levels of n-3 PUFAs are signiﬁcantly associated with higher
prevalence of vulnerable plaques [9]. Moreover, n-3 PUFAs may
have a beneﬁcial effect in addition to PCI in not only in patients
with AMI but also those with stable angina. A study has shown that
n-3 PUFAs levels are negatively correlated with incidence of peri-
procedural injury in elective PCI [10]. Taken together, there is also a
possibility that treatment with n-3 PUFAs may reduce plaque
burden and stabilize plaque components, leading to less incidenceDOI of original article: http://dx.doi.org/10.1016/j.jjcc.2015.03.009
http://dx.doi.org/10.1016/j.jjcc.2015.03.011
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsof complications including reperfusion injury in patients with AMI.
Thus, chronic treatment with n-3 PUFAs prior to onset of AMI may
reduce reperfusion injury and improve myocardial necrosis follow-
ing PCI even if patients unfortunately suffer from AMI. Previous
studies have suggested that chronic treatment with statins prior to
attack conferred cardioprotective effects [11,12]. Therefore, n-3
PUFAs as well as statins may be recommended in patients at high
risk for atherosclerotic events.
A recent study has reported that early n-PUFA treatment after
primary PCI in patients suffering from AMI signiﬁcantly reduced
the incidence of critical ventricular arrhythmia and also lowered
the peak C-reactive protein levels [13]. The ﬁndings suggest that n-
PUFAs have anti-inﬂammatory effects and preventive effects
against reperfusion injury even if they are administered after
onset of AMI or after primary PCI.
One of the important points of the study by Arakawa et al. is
that they used precise data of electrocardiograms (ECG). It is well
known that ST-resolution and QRS score can predict clinical
outcome. ECG is the simple and cheap option in patients with
ischemic heart disease. Recent new modalities can detect
infarction size and viability of myocardium. In addition, evaluation
of angiographic or imaging for coronary artery provide us useful
information. However, we have to remember the importance of
ECG in AMI patients undergoing PCI.
In conclusion, new cardioprotective strategies and targets have
been warranted to provide much beneﬁt to patients with AMI
above those provided by myocardial reperfusion therapy alone.
The ﬁndings by Arakawa et al. provide us useful information for
clinical treatment in patients with AMI.
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